【摘要】：目的探討Lrig1、EGFR在人體胃癌組織和外周血中的表達(dá)情況和臨床意義,以及Lrig1與腫瘤標(biāo)記物CEA、CA724的聯(lián)合檢測(cè)對(duì)胃癌的診斷價(jià)值分析。方法采用免疫組化二步法檢測(cè)Lrig1和EGFR蛋白在57例胃癌組織和相應(yīng)癌旁正常胃組織中的表達(dá)情況,分析其與臨床病理參數(shù)的相關(guān)性;通過RT-PCR檢測(cè)Lri g1和EGFR m RNA在57例胃癌組織中和相應(yīng)癌旁正常胃組織的相對(duì)表達(dá)量,以及L rig1 m RNA在57例胃癌患者和健康人外周血中的相對(duì)表達(dá)量;通過電化學(xué)發(fā)光法檢測(cè)57例胃癌患者及健康人血清中CEA、CA724的表達(dá)水平,并聯(lián)合Lrig1 m RNA在外周血中的表達(dá),對(duì)結(jié)果進(jìn)行分析。結(jié)果1、Lrig1在胃癌組織中的陽性表達(dá)率(38.6%)低于正常胃組織(82.5%),而E GFR在胃癌組織中的陽性表達(dá)率(63.2%)顯高于正常胃組織(15.8%),差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。Lrig1和EGFR蛋白在胃癌組織中的表達(dá)水平呈顯著負(fù)相關(guān)(r=-0.515,P0.01)。Lrig1蛋白的表達(dá)與胃癌患者的性別、年齡、腫瘤大小、分化程度、TNM分期和有無淋巴結(jié)轉(zhuǎn)移無關(guān)(P0.05),EGFR蛋白表達(dá)與患者年齡、性別、腫瘤大小無關(guān)(P0.05),而與腫瘤分化程度、TNM分期和有無淋巴結(jié)轉(zhuǎn)移密切相關(guān)(P0.01)。2、胃癌組織中Lrig1 m RNA表達(dá)水平(0.43±0.16)較相應(yīng)癌旁正常組織(1.06±0.21)降低,而EGFR m RNA表達(dá)水平(3.27±0.67)高于相應(yīng)癌旁正常組織(1.33±0.28),P0.05。Lrig1和EGFR m RNA在胃癌組織中的表達(dá)水平呈顯著負(fù)相關(guān)(r=-0.874,P0.01)。3、胃癌患者靜脈血中Lrig1 m RNA表達(dá)水平(0.73±0.21)較健康對(duì)照組(1.28±0.27)降低(P0.05)。4、胃癌患者血清CEA(39.6±16.5)、CA724(58.8±19.6)水平明顯高于對(duì)照組CEA(3.3±1.2)、CA724(4.5±1.7),P0.05,且胃癌患者血清中CE A(54.4%)、CA724(73.7%)陽性率明顯高于對(duì)照組CEA(14.0%)、CA724(8.8%),P0.05,胃癌患者靜脈血中Lrig1 m RNA的表達(dá)陽性率(49.1%)明顯低于對(duì)照組(87.7%),P0.05。Lrig1和CEA、CA724在胃癌患者靜脈血中和健康對(duì)照組靜脈血中的表達(dá)水平呈負(fù)相關(guān)(r=-0.509,P0.01;r=-0.369,P0.01)。Lrig1和CEA、CA724三者聯(lián)合檢驗(yàn)的敏感性和特異性高于單一檢測(cè)的結(jié)果。結(jié)論1、Lrig1在胃癌組織中存在低表達(dá),提示Lrig1在參與胃癌的發(fā)生發(fā)展過程中可能起著抑癌基因的作用,其表達(dá)并不能決定胃癌的病理分型;EGFR在胃癌組織中的高表達(dá)提示EGFR可能在胃癌的發(fā)病機(jī)制中和生長(zhǎng)增殖中發(fā)揮關(guān)鍵作用。2、胃癌組織中Lrig1與EGFR的表達(dá)呈負(fù)相關(guān),提示Lrig1可能存在對(duì)EGFR的負(fù)反饋調(diào)節(jié),二者在正常情況下保持一定的平衡。3、腫瘤標(biāo)志物CEA和CA724對(duì)胃癌均有一定的敏感性和特異性,Lrig1 m R NA與其聯(lián)合檢測(cè)提高了對(duì)胃癌診斷的敏感性和特異性,這對(duì)胃癌的早期防治和跟蹤治療有很大的參考價(jià)值。
[Abstract]:Objective to investigate the expression and clinical significance of Lrig1,EGFR in human gastric cancer tissues and peripheral blood, and to analyze the diagnostic value of Lrig1 combined with tumor marker CEA,CA724 in gastric cancer. Methods Immunohistochemical two-step method was used to detect the expression of Lrig1 and EGFR protein in 57 cases of gastric cancer and adjacent normal gastric tissues, and the correlation between the expression and clinicopathological parameters was analyzed. The relative expression of Lri G1 and EGFR m RNA in 57 cases of gastric cancer and the corresponding normal gastric tissues were detected by RT-PCR, and the relative expression of L rig1 m RNA in peripheral blood of 57 cases of gastric cancer and healthy persons was also detected. The expression of CEA,CA724 in serum of 57 patients with gastric cancer and healthy persons was detected by electrochemiluminescence, and the expression of Lrig1 m RNA in peripheral blood was analyzed. Results 1the positive expression rate of Lrig1 in gastric cancer tissues (38.6%) was lower than that in normal gastric tissues (82.5%), while the positive expression rate of E GFR in gastric cancer tissues (63.2%) was significantly higher than that in normal gastric tissues (15.8%). The difference was statistically significant (P0.05). There was a significant negative correlation between the expression of Lrig1 and EGFR in gastric cancer tissues (r-0.515, P0.01). The expression of Lrig1 protein was correlated with the sex, age, tumor size, differentiation degree of gastric cancer patients. TNM stage was not related to lymph node metastasis (P0.05), EGFR protein expression was not related to age, sex and tumor size (P0.05), but was closely related to tumor differentiation, TNM stage and lymph node metastasis (P0.01). The expression of Lrig1 m RNA in gastric cancer (0.43 鹵0.16) was significantly lower than that in adjacent normal tissues (1.06 鹵0.21), while the expression of EGFR m RNA was (3.27 鹵0.67) higher than that in adjacent normal tissues (1.33 鹵0.28). The expression of P0.05.Lrig1 and EGFR m RNA in gastric carcinoma was negatively correlated (r = -0.874, P 0.01). The expression of Lrig1 m RNA in the venous blood of gastric cancer patients (0.73 鹵0.21) was significantly lower than that in the healthy controls (1.28 鹵0.27) (P0.05), and the serum CEA level in gastric cancer patients was (39.6 鹵16.5). The levels of CA724 (58.8 鹵19.6) were significantly higher than those of control group (3.3 鹵1.2), CA724 (4.5 鹵1.7), P0.05, and the serum CE A (of gastric cancer patients was 54.4%. The positive rate of CA724 (73.7%) was significantly higher than that of control group (14.0%), CA724 (8.8%), P0.05. The positive rate of Lrig1 m RNA expression in venous blood of gastric cancer patients (49.1%) was significantly lower than that of control group (87.7%). There was a negative correlation between the expression of P0.05.Lrig1 and CEA,CA724 in the venous blood of gastric cancer patients and the healthy control group (r = -0.509, P 0.01). The sensitivity and specificity of Lrig1 and CEA,CA724 combined detection were higher than that of single detection. Conclusion 1 the low expression of Lrig1 in gastric carcinoma suggests that Lrig1 may play an important role in the carcinogenesis and development of gastric cancer, and its expression can not determine the pathological type of gastric cancer. The high expression of EGFR in gastric cancer suggests that EGFR may play a key role in the pathogenesis and growth of gastric cancer. 2There is a negative correlation between Lrig1 and EGFR expression in gastric cancer, suggesting that Lrig1 may have negative feedback regulation on EGFR. The tumor markers CEA and CA724 have a certain sensitivity and specificity for gastric cancer. The combined detection of Lrig1 m R NA and CA724 improves the sensitivity and specificity of the diagnosis of gastric cancer. It has great reference value for early prevention and treatment of gastric cancer.
【學(xué)位授予單位】：遼寧醫(yī)學(xué)院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R735.2

【共引文獻(xiàn)】

相關(guān)期刊論文 前7條

1 張小輝;金仁順;;胃癌組織中EGFR和TGF-α的表達(dá)及意義[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;2014年06期

2 華濤濤;趙硯瑾;錢鵬宇;李艷陽;吳智鴻;葉清泉;李庶心;;4-(吡啶-2-甲氧基)-5,6,7,8-四氫萘酚-1-胺的合成[J];精細(xì)化工中間體;2015年01期

3 王曉倩;史永華;常珩;塔拉甫·托坎;美力班·吐爾遜;;表皮生長(zhǎng)因子受體信號(hào)通路在維吾爾族婦女宮頸癌中的表達(dá)研究[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2014年20期

4 劉志敏;呂申;;胃癌中hMSH2表達(dá)缺失對(duì)EGFR及KRAS基因突變影響的研究[J];現(xiàn)代腫瘤醫(yī)學(xué);2014年12期

5 劉坤;王海江;孫振強(qiáng);許睿瑋;于顯博;胡翰峰;;胃癌組織HER-2和VEGF及EGFR表達(dá)臨床意義研究[J];中華腫瘤防治雜志;2015年10期

6 黃亞妮;龔彩鳳;潘金華;;西妥昔單抗治療晚期結(jié)直腸癌研究進(jìn)展[J];中國(guó)腫瘤生物治療雜志;2014年05期

7 董晨;李紅;;胃癌組織中Lrig1與EGFR基因表達(dá)[J];中國(guó)公共衛(wèi)生;2015年06期

相關(guān)碩士學(xué)位論文 前1條

1 楊波波;不同腫瘤基因表達(dá)分析中內(nèi)參基因的選擇和研究[D];西北大學(xué);2014年

，

本文編號(hào)：2358073